CD4 and neoplasm: These results suggests that the MHC class II semiallogeneic bm12 mBMDC vaccination is CD4+ T cell dependent only at the early stages of the tumor growth, but depletion of CD4+ T cells during the later stages of tumor growth and treatment enhances mBMDC-mediated tumor suppression through improving E7-specific CD8+ T cell responses.